CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
Conditions
- T Lymphoblastic Leukemia/Lymphoma
- Extramedullary NK-T-cell Lymphoma, Nasal Type
- Peripheral T-cell Lymphoma, Nonspecific
- Angioimmunoblastic T-cell Lymphoma
- Enteropathy-Associated T-Cell Lymphoma
- Anaplastic Large Cell Lymphoma, ALK-negative
- T-cell Lymphoblastic Leukemia
Interventions
- BIOLOGICAL: T cell injection targeting CD7 chimeric antigen receptor
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators